The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog is intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Support this site

    If you found the information here helpful, please consider supporting this site.If you found the information here helpful, please consider supporting this site.

  • Recent Posts

  • Recent Comments

    Risk of curcumin-drug interactions

    Researchers at Central South University, in Hunan, China studied the effect of curcumin (turmeric) on drug metabolizing enzymes.

    Their findings suggest a risk for curcumin-drug interactions.

    First, the details.

    • 16 healthy Chinese men were recruited for the study.
    • There were 2 phases.
      • First phase, volunteers received 100 mg caffeine by mouth and 0- to 12-hour blood and urine samples were collected.
      • Second phase, volunteers received 1000 mg curcumin once daily for 14 continuous days, with blood and urine samples were collected on days 1 and 15.
    • Caffeine metabolites (eg 17X, 17U) in the urine were used as the indicators of the activities of 4 enzymes: cytochrome P450 enzymes (CYP1A2 and CYP2A6), N-acetyltransferase type 2 (NAT2), and xanthine oxidase (XO).
      • CYP1A2 and CYP2A6 are members of the “superfamily” of liver enzymes, which alter the rate of drug metabolism and synthesis of cholesterol, steroids and other lipids.
      • NAT2 and XO participate in detoxification of foreign substances in the body.
    • The pharmacokinetics of caffeine and its metabolites were measured using high-performance liquid chromatography.

    And, the results.

    • When taking curcumin…
      • CYP1A2 activity significantly decreased 29%.
      • CYP2A6 activity significantly increased 49%.
      • The area under the concentration-time curve (a measure of how much drug is absorbed) from 0 to 12 hours of 17X significantly decreased 27%.
      • Urinary excretion of 17X and XO decreased 36% and 31%, respectively.
      • Excretion of 17U significantly increased 77%.
    • There were no significant changes for caffeine, 1-methylurate, and 5-acetylamino-6-formylamino-3-methyluracil between the 2 study phases.

    The bottom line?

    The authors concluded, “Curcumin inhibits CYP1A2 function but enhances CYP2A6 activity. Simultaneously, some pharmacokinetic parameters relating to 17X were affected by curcumin.”

    No actual curcumin-drug interaction has been reported, but there is a risk that should be considered when patients are evaluated.

    5/20/10 17:09 JR

    Leave a Comment

    You must be logged in to post a comment.